Glaukos
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Glaukos and other ETFs, options, and stocks.About GKOS
Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology.
GKOS Key Statistics
GKOS News
Glaukos (GKOS) remains unprofitable as losses have increased at a rate of 14.6% per year for the past five years, and the company’s net profit margin has shown...
The company's recent past featured robust growth, and it anticipates continued rises into the near future. Glaukos (GKOS +13.89%), a biotech and pharmaceutical...
Earnings Call Insights Glaukos outlines $600M–$620M 2026 revenue outlook as Epioxa launch and iDose TR drive growth Oct. 30, 2025 12:07 AM ET Glaukos Corporatio...
Analyst ratings
93%
of 15 ratingsMore GKOS News
Reports Q3 revenue $133.5M, consensus $122.6M. “Our record third quarter results reflect continued strong momentum in our business driven by successful global e...
Glaukos, a leader in ophthalmic therapies, has just secured FDA approval for Epioxa, a new incision-free topical treatment for keratoconus. This milestone repre...